The results of the present study showed a significant difference in the mean levels of IL-6 among the three different treatment groups, which indicates that controlling stress and anxiety as well as depression is beneficial for achieving a successful treatment outcome in TMD patients. This evidence concerns the gene IL6 and depressive symptom measurement.